Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1891
Not yet recruiting
1
100.0%
No approval data available
- Genyro Inc. has secured exclusive licensing rights to Sidewinder™ technology from Caltech, a breakthrough DNA construction method based on DNA 3-Way Junctions that enables accurate assembly of long, complex DNA sequences. - The technology achieves a remarkably low misconnection rate of just one in a million, dramatically improving upon conventional methods that have error rates of one in 10 to one in 30. - Sidewinder uses removable "DNA page numbers" as assembly guides, allowing parallel construction of DNA fragments and overcoming historical limitations in building repetitive or GC-rich sequences. - The platform has potential applications across medicine, materials, agriculture, and biotechnology, including vaccines, gene therapies, and AI-designed biological systems.
- Researchers have developed sand-grain-sized microrobots that can swim through blood vessels using magnetic guidance to deliver drugs with millimeter precision before dissolving safely in the body. - The gelatin-based robots demonstrated over 95% accuracy in drug delivery to correct locations during trials in pigs and sheep, representing a significant advance toward clinical translation. - The technology addresses a critical need in drug development, where approximately one-third of developed drugs fail due to toxicity from systemic exposure rather than targeted delivery. - The modular platform integrates electromagnetic navigation, real-time X-ray tracking, and biodegradable materials, potentially enabling clinical applications within five to ten years.
- California Institute of Technology researchers successfully transitioned their iCares smart bandage system from animal models to human clinical testing, enrolling 20 patients with diabetic foot ulcers and venous leg wounds. - The smart bandage demonstrated the ability to detect critical biomarkers including nitric oxide, hydrogen peroxide, and oxygen levels one to three days before patients experienced clinical symptoms. - The device's machine learning algorithm successfully classified wound severity and healing potential with accuracy comparable to experienced clinicians, providing objective wound assessment capabilities. - The technology represents a significant advancement over traditional wound monitoring methods by enabling real-time continuous monitoring of wound biomarkers through an innovative microfluidic system.
- The global nanorobots for drug delivery market is projected to grow from $1.22 billion in 2025 to $1.73 billion by 2030, representing a CAGR of 7.05% as demand for targeted therapeutic solutions increases. - Exogenous power-driven nanorobots are emerging as leaders in next-generation chemotherapy and radiotherapy applications, offering unprecedented precision in delivering medications directly to disease sites. - Leading research institutions including California Institute of Technology, Karolinska Institutet, and the Koch Institute are driving innovations that have demonstrated up to 70% tumor reduction in preclinical studies.
- A novel mosaic-8b nanoparticle vaccine is under development to provide broad cross-reactive immunity against known and future sarbecovirus strains, enhancing pandemic preparedness. - The vaccine targets conserved regions of the receptor-binding domain (RBD) shared by all SARS-like betacoronaviruses, aiming to overcome the limitations of current vaccines due to viral mutations. - Pre-clinical research indicates the mosaic-8b vaccine triggers robust immune responses, even after prior SARS-CoV-2 exposure, generating broadly cross-reactive antibodies. - Engineering biology CRDMO Ingenza has partnered with other organizations to formulate the vaccine, utilizing microbial platforms to reduce development time and costs.
